Alleged “Off-Label” Zofran (ondansetron) Promotion Left Many Women in the Dark

Drug giant GlaxoSmithKline (“GSK”) has come under fire in recent months for its alleged “off-label” promotion of anti-nausea medication Zofran (ondansetron) for use by pregnant women, despite the drug never having been deemed safe for expectant mothers. Zofran (ondansetron), when taken during the first trimester of pregnancy, has been linked to severe birth defects including cleft lip and heart malformations. Lawsuits are being filed all over the United States, with many plaintiffs claiming that they had no way of knowing that Zofran (ondansetron) was a unsafe treatment for morning sickness. Many mothers felt much like GSK’s “guinea pigs,” as effects of the drug hadn’t been studied on pregnant women before their children were exposed to the drug and its serious side effects.

Real Time Analytics